Pressure Biosciences : Pressure BioSciences, Inc. Upgraded by EdgeWater Research Partners LLC
12/27/2006| 10:48am US/Eastern
Recommend:
Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that in an
update to an initial research report on the Company, EdgeWater Research
Partners LLC (?EdgeWater?)
has upgraded PBI's rating from a 4 to a 6 and
re-established a 12-18 month price target. Of the 20 companies currently
covered by EdgeWater, only one has a rating greater than 6.
Copies of the updated and initial research reports on PBI can be
obtained free of charge by contacting Mr. David Lavigne at EdgeWater (www.edgewaterresearch.com
or 303-593-2877).
Analyst Coverage Disclaimer
Pressure BioSciences is announcing the availability of EdgeWater's
updated research report solely for convenience. Any opinions, estimates,
or forecasts regarding Pressure BioSciences'
historical or predicted performance or operations, including predictions
of stock price, made by EdgeWater are theirs alone and do not represent
opinions, judgments, estimates, or forecasts of Pressure BioSciences or
its management. Pressure BioSciences does not endorse, adopt, or concur
with information, conclusions, or recommendations in either EdgeWater's
initial or updated research reports on the Company. Pressure BioSciences
subscribes for EdgeWater's newsletter and
research information, and has purchased EdgeWater's
research reports. For the past two years, Pressure BioSciences has paid
a fee of $8000 to attend and present at EdgeWater's
fall Micro/Small Cap Conference for Investment Professionals.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage
company focused on the development of a novel, enabling technology
called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic
pressure between ambient and ultra-high levels (up to 35,000 psi and
greater) to control bio-molecular interactions. PBI currently holds 13
US and 5 foreign patents covering multiple applications of PCT in the
life sciences field, including such areas as genomic and proteomic
sample preparation, pathogen inactivation, the control of enzymes,
immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future
are "forward-looking'' statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These risks, uncertainties,
and other factors include, but are not limited to, the risks and
uncertainties discussed under the heading "Risk Factors" in the Company's
Quarterly Report on Form 10-QSB for the quarter ended September 30,
2006; in the Company's Annual Report on Form
10-KSB, as amended, for the year ended December 31, 2005; and other
reports filed by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included in
this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
© Business Wire 2006
Recommend :
